What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study

Published:2015-11-26 Issue:4 Volume:34 Page:393-402
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Harris Anthony,Li Jing Jing,Yong Karen

Funder

Australian Research Council

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-015-0354-z.pdf

Reference24 articles.

1. Drummond M, Jönsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy. 1997;40(3):199–215.

2. Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007;82(3):330–9.

3. Paris V, Belloni A. Value in pharmaceutical pricing. OECD Health Working Papers no. 63. Paris: OECD Publishing; 2013.

4. Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. 2014;32(4):319–25.

5. Nash J. Two-person cooperative games. Econometrica. 1953;21(1):128–40.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee;PharmacoEconomics;2024-08-24

2. Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications;Australian Health Review;2022-12-22

3. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia;Journal of Neurology;2022-08-18

4. Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020;Value in Health;2021-12

5. Towards Smarter Public Budgeting? Understanding the Potential of Artificial Intelligence Techniques to Support Decision Making in Government;The 21st Annual International Conference on Digital Government Research;2020-06-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3